Illumina’s third quarter results reflected stable year-over-year revenue and a notable beat on Wall Street’s profit ...

Illumina Inc. said the Chinese government has lifted a ban on the company selling its DNA sequencing machines inside the country.

Genomics company Illumina (NASDAQ:ILMN) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...

We recently published 10 Firms Dominating the Market; 5 at All-Time Highs. Illumina, Inc. (NASDAQ:ILMN) is one of the ...

On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...

Discover key Q3 2025 earnings insights for Illumina, including raised outlook, NovaSeq X growth, and margin expansion.

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

Founded by former Illumina, Grail and Google leaders, Hepta is applying the technological, genomic and commercialization expertise that made liquid biopsy possible in oncology to the far larger field ...

Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on ...

Investing.com -- Illumina Inc (NASDAQ:ILMN) reported better-than-expected third-quarter results on Thursday, with earnings surpassing analyst estimates and the company raising its full-year outlook, ...